Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Yaseen M ArabiAyed Y AsiriAbdullah M AssiriHani A Aziz JokhdarAdel AlothmanHanan H BalkhySameera AlJohaniShmeylan Al HarbiSuleiman KojanMajed Al JeraisyAhmad M DeebZiad A MemishSameeh GhazalSarah Al FarajFahad Al-HameedAsim AlSaediYasser MandourahGhaleb A Al MekhlafiNisreen Murad SherbeeniFatehi Elnour ElzeinAbdullah AlmotairiAli Al BshabsheAyman KharabaJesna JoseAbdulrahman Al HarthyMohammed Al SulaimanAhmed MadyRobert A FowlerFrederick G HaydenAbdulaziz Al-DawoodMohamed AbdelzaherWail BajhmomMohamed A Husseinnull nullPublished in: Trials (2020)
The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02845843. Registered on 27 July 2016.
Keyphrases
- study protocol
- phase iii
- randomized controlled trial
- placebo controlled
- phase ii
- double blind
- clinical trial
- combination therapy
- sars cov
- open label
- healthcare
- respiratory syndrome coronavirus
- dendritic cells
- type diabetes
- squamous cell carcinoma
- immune response
- risk factors
- quality improvement
- chronic pain
- affordable care act
- coronavirus disease
- coronary artery disease
- health insurance
- antiretroviral therapy
- replacement therapy